The ALS Association Responds to Inquiries on Genervon Drug Candidate

January 19, 2015

Numerous individuals have contacted The ALS Association requesting assistance in the promotion of patient access to a drug candidate called GM6 in development by Genervon Biopharmaceuticals LLC.

Genervon recently issued a press release regarding its submission of results to the U.S. Food and Drug Administration (FDA) of its single patient compassionate use trial for GM6. The company had announced the results of their Phase 2A clinical trial of the drug in October 2014.

The ALS Association has engaged Genervon to learn more about the trial results and the company’s plans for moving forward with the FDA and clinical development. Those discussions will inform next steps and what role The Association will play as the drug advances in the development process.  

As always, The ALS Association is committed to doing everything possible to advance therapies for ALS, working closely with pharmaceutical companies and the U.S. Food and Drug Administration.

Powered by Blackbaud
nonprofit software